Details for Patent: 6,756,033
✉ Email this page to a colleague
Title: | Method for delivering benzindene prostaglandins by inhalation |
Abstract: | A method of delivering benzindene prostaglandins to a patient by inhalation is discussed. A benzindene prostaglandin known as UT-15 has unexpectedly superior results when administered by inhalation compared to parenterally administered UT-15 in sheep with induced pulmonary hypertension. |
Inventor(s): | Cloutier; Gilles (Chapel Hill, NC), Crow; James (Chapel Hill, NC), Wade; Michael (Chapel Hill, NC), Parker; Richard E. (Spring Hill, TN), Loyd; James E. (Nashville, TN) |
Assignee: | United Therapeutics Corporation (Washington, DC) |
Filing Date: | Aug 06, 2002 |
Application Number: | 10/212,149 |
Claims: | 1. A method of delivering to a mammal in need thereof a therapeutically effective amount of a benzindene prostaglandin comprising administering to the mammal by inhalation a formulation comprising droplets measuring less than 10 micrometers in diameter, wherein said droplets comprise a therapeutically effective amount of the benzindene prostaglandin. 2. The method of claim 1, wherein said the aerosolized form comprises droplets less than 10 micrometers in diameter, said droplets comprising said benzindene prostaglandin is 9-deoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor3,7-(1'3'-interphenylene)-1 3,14-dihydro-prostaglandin F.sub.1 in a suitable pharmacologically-acceptable liquid carrier. 3. The method of claim 1, wherein the mammal is a human. 4. The method of claim 1, wherein the formulation comprises a sustained release form of the benzindene prostaglandin. 5. The method of claim 1, wherein the administering of benzindene prostaglandin has no effect on heart rate. 6. A method of delivering to a mammal in need thereof a therapeutically effective amount of a benzindene prostaglandin comprising administering to the mammal by inhalation a powder formulation comprising particles measuring less than 10 micrometers in diameter, wherein said particles comprise a therapeutically effective amount of the benzindene prostaglandin. 7. The method of claim 6, wherein the benzindene prostaglandin is UT-15. 8. The method of claim 6, wherein the mammal is a human. 9. The method of claim 6, wherein the formulation comprises a sustained release form of the benzindene prostaglandin. 10. The method of claim 6, wherein the administering of the benzindene prostaglandin has no effect on heart rate. |